Organization
Royal Marsden Hospital, Institute of Cancer Research, London, United Kingdom
1 abstract
Abstract
Capivasertib (C) and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): Characterization and management of common adverse events (AEs) from the phase 3 CAPItello-291 trial.Org: University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, Medical Oncology Department and Breast Cancer Group, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, The University of Manchester, Manchester, United Kingdom, The Christie NHS Foundation Trust, Manchester, United Kingdom, Institut Claudius Regaud, Institut Universitaire du Cancer – Oncopole, Toulouse, France,